X
<

Johnson & Johnson's 1Q18 Earnings: What to Expect on April 17

PART:
1 2 3
Johnson & Johnson's 1Q18 Earnings: What to Expect on April 17 PART 1 OF 3

What to Expect from Johnson & Johnson’s 1Q18 Earnings

Johnson & Johnson’s estimates

Johnson & Johnson (JNJ), one of the largest pharmaceutical companies by revenues, is scheduled to release its 1Q18 earnings on April 17, 2018.

What to Expect from Johnson &#038; Johnson’s 1Q18 Earnings

Interested in BMY? Don't miss the next report.

Receive e-mail alerts for new research on BMY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The above chart compares Johnson & Johnson’s revenues and EPS (earnings per share) since 1Q17 and the estimates for 1Q18.

Analysts’ estimates

Wall Street analysts estimate an EPS of $2.00 on revenues of $19.4 billion during 1Q18—compared to an EPS of $1.83 on revenues of $17.8 billion during 1Q17.

Revenue estimates

Analysts expect the revenues for 1Q18 to increase ~9.2% to ~$19.4 billion—compared to revenues of $17.8 billion for 1Q17. Johnson & Johnson has segregated its business into three segments—the Pharmaceuticals segment, Consumer segment, and Medical Devices segment. For 1Q18, the increased revenues are expected to be driven by higher operating revenues for each segment.

Profitability estimates

Analysts’ estimates show a gross profit margin of 70.3% for 1Q18—a marginal increase compared to the gross profit margin in 1Q17. Due to lower research and development expenses, and lower selling, general, and administrative expenses, the EBITDA margin is expected to increase marginally to 38.6% in 1Q18—compared to 38.1% in 1Q17. The net adjusted income is expected to increase to ~$5.5 billion in 1Q18—compared to $5.0 billion in 1Q17.

Notably, the Healthcare Select Sector SPDR ETF (XLV) has 11.2% of its total investments in Johnson & Johnson, 6.9% in Pfizer (PFE), 4.9% in Merck & Co. (MRK), and 3.1% in Bristol-Myers Squibb (BMY).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!

X

Please select a profession that best describes you: